SlideShare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our User Agreement and Privacy Policy.
SlideShare uses cookies to improve functionality and performance, and to provide you with relevant advertising. If you continue browsing the site, you agree to the use of cookies on this website. See our Privacy Policy and User Agreement for details.
Successfully reported this slideshow.
Activate your 14 day free trial to unlock unlimited reading.
1.
Emma Back MeTA Consultant MeTA country guidance note ‘Moving towards medicines data transparency, joint analysis and evidence-based policies to improve access to medicines’ 8 December 2009
2.
Purpose of the guidance note <ul><li>To provide advice and guidance to MeTA pilot countries – specifically national Secretariats and multi-stakeholder groups – as they take steps towards establishing a process of routine disclosure of key medicines data. </li></ul><ul><li>To provide some tools and examples to aid this process, share case studies and lessons from different countries, and identify potential sources of TA. </li></ul><ul><li>Broader purpose: </li></ul><ul><li>The note will help to ensure standardization of reporting across MeTA countries, which will in turn aid comparison, monitoring and evaluation . </li></ul>
3.
Proposed content <ul><li>Recap of MeTA pilot phase goals and principles </li></ul><ul><li>Purpose of guidance note in this context </li></ul><ul><li>Phased approach towards increasing transparency, [accountability,] and evidence-based policy and practice; an ongoing cycle: </li></ul><ul><li>Diagnosis </li></ul><ul><li>Setting parameters; agreeing reporting format; agreeing process </li></ul><ul><li>Data collection / submission; data assessment </li></ul><ul><li>Multi-stakeholder discussion of the data </li></ul><ul><li>Data use - including for comms, advocacy and policy development </li></ul><ul><li>Reporting and monitoring </li></ul><ul><li>Using the phased approach in practice </li></ul><ul><li>Securing additional support </li></ul>
4.
Questions for you <ul><li>Does the step-wise approach make sense? </li></ul><ul><li>Will the proposed format of the guidance note give you what you need? </li></ul><ul><li>What else would you like to see in the note? What do you need most guidance on? TA priorities? </li></ul><ul><li>Do you have any case studies or lessons you would like to share through the guidance note? </li></ul><ul><li>Any data collection / disclosure / reporting formats? </li></ul>